ArticlePloS one2025
The protective role of Lactobacillus reuteri in a DSS-induced ulcerative colitis mouse model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent insights in pathogenesis of endometriosis with focus on gut microbiota.Molecular biology reports · 2026Review
- GABA-Producing Bacteria as Potential Psychobiotics in Gut-Brain Axis Regulation.International journal of molecular sciences · 2026Review
- The gut microbiome axis: how Lactobacillus-fermented soymilk orchestrates health.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon, marked by symptoms such as mucosal ulceration, diarrhea, and abdominal pain. The dextran sodium sulfate (DSS)-induced murine model replicates clinical and histological features of UC and is widely used to explore potential treatments. Lactobacillus reuteri has emerged as a promising probiotic due to its immunomodulatory and anti-inflammatory properties. This study investigates the effects of L. reuteri supplementation on histopathology, inflammatory cytokines, intestinal barrier function, and short-chain fatty acid (SCFA) production in DSS-induced colitis. Male Balb/C mice were divided into control, DSS-induced colitis, and DSS + L. reuteri treatment groups. The colitis model was established with 3% DSS in drinking water for seven days, and mice in the treatment group received 1010 CFU of L. reuteri daily. Disease activity index (DAI), colon length, myeloperoxidase (MPO) levels, cytokine concentrations, tight junction protein expression, and SCFA production were measured to evaluate treatment effects. Histological analyses assessed inflammation, crypt damage, and ulceration. Mice treated with L. reuteri exhibited significant improvements across all evaluated parameters. Supplementation mitigated weight loss, reduced DAI, and restored colon length. MPO levels and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) were significantly reduced, while anti-inflammatory IL-10 levels were elevated. Histological scores showed decreased inflammation, crypt damage, and ulceration. L. reuteri enhanced tight junction protein expression, particularly ZO-1 and Claudin-1, and significantly increased SCFA production, improving gut barrier integrity and microbial function. L. reuteri supplementation effectively mitigates DSS-induced colitis by reducing inflammation, restoring intestinal barrier integrity, and enhancing microbial metabolism. These findings suggest L. reuteri as a promising therapeutic candidate for UC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.